ArticleJournal of cutaneous pathology2026
Cutaneous Acral Presentation of Indolent Mantle Cell Lymphoma With Prominent Nail Involvement and Atypical Immunophenotype.
Article in Journal of cutaneous pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mantle cell lymphoma (MCL) is a rare, aggressive subtype of B-cell non-Hodgkin lymphoma with rare cutaneous involvement that typically indicates advanced systemic disease. We report a case of indolent MCL in a 56-year-old previously healthy male who presented with a 5-year history of edematous, painful plaques and associated onychodystrophy in the bilateral toes. Histopathology demonstrated a multinodular dermal and subcutaneous infiltrate of atypical lymphocytes. Immunohistochemistry revealed a primary B-cell population diffusely positive for CD20 and BCL2 and focally positive for BCL1. These cells were negative for CD5, SOX-11, BCL6, and LEF1. In situ hybridization demonstrated admixed lambda-restricted plasma cells, indicating plasmacytic differentiation. Fluorescence in situ hybridization testing for an IGH/CCND1 translocation was positive, confirming a diagnosis of MCL. While bone marrow biopsy demonstrated 10%-20% involvement by MCL, staging revealed no lymphadenopathy or visceral disease. No significant peripheral blood laboratory abnormality was noted. To our knowledge, this is the first reported case of cutaneous involvement by MCL confined to the bilateral toes. This case is also notable for its absence of typical markers, namely CD5 and SOX-11, plasmacytic differentiation, and indolent clinical behavior. We discuss the diagnostic and clinical significance of these atypical clinicopathologic features and diagnostic overlap with other cutaneous B-cell lymphomas, emphasizing the importance of comprehensive immunophenotypic and molecular evaluation in atypical presentations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.